Virtus Real Asset Income ETF (ARCA: VRAI)

Últimas noticias sobre Virtus Real Asset Income ETF (ARCA:VRAI)

Energy

Real Estate

Utilities

Basic Materials

Communication Services

Healthcare

Consumer Defensive

Other

Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the underlying index. The underlying index is designed to track the performance of U.S.-listed Real Asset companies, as defined by Indxx, LLC. The underlying index includes common stock, real estate investment trusts, master limited partnerships, American depositary receipts and global depositary receipts. The fund is non-diversified.

Cogent Communications Hold Inc

One Gas Inc

Outfront Media Inc

Plains All American Pipeline, L.p., Series B

Sitio Royalties Corp-A

Gerdau Sa Adr

Plains Gp Holdings Lp

Western Midstream Partners Lp

Patterson-Uti Energy Inc

Virtus Real Asset Income ETF

Equities

Large Cap

News

Contracts

FTRI

VRAI

Ecopetrol y Oxy expanden su plan de perforación en la Cuenca Pérmica con 34 nuevos pozos. Impacto en la producción y las inversiones.

Ecopetrol y Occidental amplían desarrollo en la Cuenca Pérmica: ¿Oportunidad de inversión?

General

TETAA

Telesat And QEST Quantenelektronische Systeme Sign Development Contract For Telesat Lightspeed Aero Flat Panel Antenna

Design Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGN#NASDAQ">DSGN</a>) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.28) by 14.29 percent. This is a 14.29 percent decrease over losses of $(0.21) per share from the same period last year.

Earnings

Earnings Beats

DSGN

Design Therapeutics Q4 2024 GAAP EPS $(0.24) Beats $(0.28) Estimate

GDS Holdings Limited ("GDS Holdings", "GDS" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>, HKEX: 9698))), a leading developer and operator of high-performance data centers in China, today announced that it has entered into definitive agreements to monetize, on a net basis, a 70% equity interest in certain of its data centers, at an implied enterprise value ("EV") to EBITDA multiple of around 13 times. In a first of a kind transaction, GDS is selling a 100% equity interest in certain data center project companies to a private REIT ("P-REIT"), which is a special purpose equity scheme involving the issue of an Asset Backed Security ("ABS"). The ABS is 70% subscribed by top tier institutional investors in China, led by China Life Insurance Company Limited ("China Life"), whilst GDS subscribes for the remaining 30% and retains the rights for on-going operation of the underlying data centers. The ABS will be listed on the Shanghai Stock Exchange as a standardized security product. The P-REIT structure is specifically designed to facilitate an eventual injection of the ABS into a public REIT vehicle ("C-REIT") when qualified.
The total EV for the transaction is up to approximately RMB 2.9 billion. The total equity consideration is up to approximately RMB 1.7 billion, or RMB 1.2 billion net of the 30% reinvestment by GDS in the ABS. GDS will receive net cash proceeds of approximately RMB 500 million at closing. The remaining net cash proceeds of approximately RMB 700 million will be paid when certain milestones are met related to the ramp-up of the underlying data centers. GDS will deconsolidate the data center project companies including existing debt and other net liabilities of around RMB 1.2 billion at closing.

Asset Sales

GDS Sells 70% Stake in Data Centers to China Life-Led Group in $400M Deal, Plans Future Public REIT Listing

RGNX

REGENXBIO Plans To Present New Interim Biomarker Data From Phase I/II Portion Of AFFINITY DUCHENNE Trial Of RGX-202 At 2025 MDA Clinical & Scientific Conference

Management

FXNC

First National Corporation Appoints Brad Schwartz As President And CFO

NLSP

NLS Pharmaceutics Issues Shareholder Update: Merger Progress, Pipeline Growth, And 18-Month Financial Runway Detailed

&nbsp;<a href="http://www.nlspharma.com/">NLS Pharmaceutics Ltd.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NLSP#NASDAQ">NLSP</a>), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, today issued a letter to its shareholders.
<a href="https://mma.prnewswire.com/media/2637716/NLS_Pharmaceutics_Logo.html"><img src="https://mma.prnewswire.com/media/2637716/NLS_Pharmaceutics_Logo.jpg" alt="NLS Pharmaceutics Logo" /></a>
Dear Shareholders,
We are thrilled to share the significant progress and strategic milestones NLS Pharmaceutics has achieved, positioning our company for a transformative future in the biotechnology sector.
Strategic Merger with Kadimastem
In November 2024, we announced a definitive merger agreement with <a href="http://www.kadimastem.com/">Kadimastem Ltd.</a>&nbsp;(TASE: KDST) ("Kadimastem"), a clinical-stage cell therapy company specializing in "off-the-shelf" allogeneic cell products for neurodegenerative diseases and diabetes. This merger aims to create a Nasdaq-traded biotechnology company with a robust portfolio of advanced therapies. Both companies' boards of directors have unanimously approved the transaction, with Kadimastem's shareholders recently voting in favor and NLS major shareholders holding approximately 40% of NLSs' common shares having signed support letters for the NLS shareholders' meeting to be convened soon. We currently anticipate closing the merger in the second quarter of 2025, pending effectiveness of NLSs' pending registration statement filed with the Securities and Exchange Commission ("SEC"), Nasdaq approval, NLSs' shareholders' approval and customary closing conditions.&nbsp;
Regulatory Filings and Approvals
We filed a Registration Statement on Form F-4 and subsequent amendment with the SEC, detailing the proposed merger with Kadimastem. This filing is a necessary step toward finalizing the merger and creating a combined entity focused on innovative therapies.&nbsp;In addition, we have submitted an application to list the merged company on Nasdaq under the name of "NucelX Ltd.", with the future ticker of NCEL.
Advancements in Diabetes Treatment
In collaboration with iTolerance Inc., Kadimastem has successfully completed a pre-Investigational New Drug ("pre-IND") meeting with the U.S. Food and Drug Administration ("FDA") for iTOL-102, a potential breakthrough therapy for Type 1 Diabetes. This innovative approach combines Kadimastem's IsletRx cells with iTolerance's immunomodulator, aiming to cure Type 1 Diabetes without the need for lifelong immune suppression.&nbsp;
The diabetes treatment landscape has experienced significant growth, underscored by notable mergers and acquisitions. For instance, Novo Nordisk's acquisition of Inversago Pharma for up to $1.075 billion highlights the strategic emphasis on developing novel therapies for obesity, diabetes, and related metabolic disorders. Similarly, Roche's $2.7 billion acquisition of Carmot Therapeutics reflects their concerted effort to expand into the diabetes and obesity markets. Additionally, Sana Biotechnology has made significant advancements in the diabetes space, with early clinical data suggesting their hypo immune platform could enable insulin production without immunosuppression, positioning them as a potential leader in developing transformative treatments for type 1 diabetes. We believe that these developments underscore the sector's robust growth and the immense potential it holds for innovative treatments.&nbsp;
Furthermore, we are expanding our diabetes treatment strategies beyond GLP-1 therapies. By integrating complementary approaches, we aim to address the multifaceted challenges of diabetes management, including neuroinflammation and metabolic resilience.&nbsp;
Advancements in Neurodegenerative Disease Treatment
Post-merger, we plan to prepare and initiate a Phase IIa multi-site clinical trial of AstroRx&#xAE;, Kadimastem's product candidate for Amyotrophic Lateral Sclerosis (ALS). This trial is slated to commence following the merger's completion, marking significant progress in our neurodegenerative disease treatment pipeline.&nbsp;
Experienced International Leadership Team&nbsp;
We believe that Kadimastem contributes to the merger with its experienced international leadership team and board of directors, and with the teams prior experience developing medicine from the laboratory to the market.&nbsp;For example,&nbsp;Rebif&#xAE;, a blockbuster drug invented by Professor Michel Revel, Chief Scientist at Kadimastem, in his capacity as a scientific investigator at the world-renowned Weizmann Institute of Science, was acquired by Merck Serono. In addition, Ronen Twito, Kadimastem's Executive Chairman and Chief Executive Officer, brings extensive experience working in the U.S. capital market and M&amp;A international market.
Advancements in DOXA R&amp;D Programs
Our promising Dual Orexin Receptor Agonist ("DOXA") platform has made significant strides. The development of AEX-41 and AEX-2 compounds showcases our dedication to addressing unmet needs in sleep-wake disorders. Preliminary studies have yielded promising results, reinforcing our confidence in these compounds' potential to transform patient care.
Additional Pipeline Expansion and Research Initiatives
Our commitment to addressing critical health challenges remains steadfast:
<ul>
<li>Fentanyl Dependence Treatment: We have launched a preclinical program evaluating Mazindol ER as a treatment for fentanyl dependence, aiming to offer a non-opioid alternative in combating the opioid crisis.</li>
<li>Advancing Scientific&nbsp;Research: Our recent submissions to and upcoming poster presentation at the American Society of Clinical Psychopharmacology's 2025 Annual Meeting highlight our commitment to innovative therapeutic strategies and groundbreaking research.</li>
</ul>
Financial Resilience and Growth
We have fortified our financial foundation through strategic initiatives:
Nasdaq &amp; Strong Financial Position
<ul>
<li>We carry zero long-term debt, a rarity among biopharmaceutical companies. This strong financial position provides us with flexibility to execute our strategic goals without financial constraints.</li>
<li>We raised approximately $4.2 million pursuant to private placements in October and December 2024, at a premium to market price. We currently believe that the amounts raised in these private placements has extended our operational runway to approximately 18 months.</li>
<li>This financial stability empowers us to accelerate clinical development, pursue strategic partnerships, and advance our innovative pipeline with confidence.</li>
</ul>
Looking Ahead
The momentum generated by these developments underscores our commitment to delivering life-changing therapies. We aim to capitalize on emerging opportunities within the dynamic biotechnology landscape, driving NLS Pharmaceutics toward a future of unparalleled success.
As we embark on this exciting new chapter, we remain laser-focused on:
<ul>
<li>Building an international, strong, well-balanced pipeline and top-notch biotechnology company</li>
<li>Delivering life-changing therapies for patients worldwide</li>
<li>Expanding our pipeline through innovation &amp; strategic collaborations</li>
<li>Maximizing shareholder value by maintaining a strong financial position</li>
</ul>
We extend our deepest gratitude to our shareholders, partners, and supporters for your trust and commitment. Together, we are building a future of unparalleled success for NLS Pharmaceutics.
Sincerely,
Alex Zwyer Chief Executive Officer &nbsp;

NLS Pharmaceutics Merger With Kadimastem Aims to Create Nasdaq-Traded Biotech Powerhouse With Therapies, Highlights Diabetes, ALS, and Opioid Treatment Advances, Signals Strong Growth Ahead With Clean Balance Sheet

All future vehicles under Geely's Galaxy brand will be equipped with G-Pilot, including the recently launched Galaxy E8 sedan.

ECARX's Skyland Pro Intelligent Driving Solution Will Be Integrated Into Geely's G-Pilot Unified Intelligent Driving System

ATEX

Anterix Launches Its AnterixAccelerator Initiative With Investment Of Up To $250M

Leveraging its differentiated commercial infrastructure, NeoGenomics expects to grow incremental topline revenue with contributions from the acquired business while operational consolidation efforts and synergies are expected to yield substantial annual cost reductions, which will be accretive to AEBITDA starting in 2026.

Health Care

NeoGenomics Acquired Pathline, Strengthening The Company's Commercial Presence In The Northeast U.S., Expanding Its Service Capabilities And Accelerating Growth In Molecular And Hematology-oncology Testing, Deal Terms Were Not Disclosed

NOVA

Sunnova Appoints Paul Mathews As President And Chief Executive Officer

TECH

Bio-Techne Commences Shipping The Leo System, Powered By Simple Western Technology

TSEM

Tower Semiconductor, Innolight Expand Collaboration Utilizing Newest Silicon Photonics Platform, Now In Production And Ramping To High Volume

JP Morgan analyst Mark Murphy upgrades DocuSign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) from Underweight to Neutral and raises the price target from $70 to $75.

Upgrades

Price Target

Analyst Ratings

DOCU

JP Morgan Upgrades DocuSign to Neutral, Raises Price Target to $75

FCEL

Diversified Energy, FuelCell Energy And TESIAC To Form An Acquisition And Development Company Focus On Net-Zero Power From Natural Gas And Captured Coal Mine Methane

<ul>
<li>Launch-HTN met its primary endpoint with lorundrostat 50 mg dose achieving a 16.9 mmHg reduction in systolic blood pressure, and a 9.1 mmHg placebo-adjusted reduction (p-value &lt; 0.0001) assessed by automated office blood pressure at week 6.</li>
<li>Launch-HTN met a predefined endpoint with lorundrostat 50 mg dose achieving a 19.0 mmHg reduction in systolic blood pressure, and an 11.7 mmHg placebo-adjusted reduction (p-value &lt; 0.0001) assessed by automated office blood pressure at end of treatment, week 12.</li>
<li>Advance-HTN met its primary endpoint with lorundrostat 50 mg dose achieving a highly statistically significant 7.9 mmHg placebo-adjusted reduction assessed by 24hr ABPM at end of treatment, week 12.</li>
<li>Lorundrostat demonstrated a favorable safety and tolerability profile in both pivotal trials</li>
</ul>

Biotech

MLYS

Mineralys Therapeutics Announced Topline Data From Its Pivotal Launch-HTN Phase 3 And Pivotal Advance-HTN Phase 2 Trials Of Lorundrostat For Uncontrolled Hypertension Or Resistant Hypertension, Both Trials Met Its Primary Endpoint

ALKT

Alkami Technology Intends To Offer $300M Of Convertible Senior Notes Due 2030 In Private Offering

HC Wainwright &amp; Co. analyst Ed Arce maintains Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Buy and raises the price target from $24 to $35.

CDTX

HC Wainwright & Co. Maintains Buy on Cidara Therapeutics, Raises Price Target to $35

SMTK

Smartkem Appoints Jonathan Watkins As COO

RDFN

Rocket Companies To Acquire Redfin In All-Stock Transaction Of $12.50/Share; Rocket Expects Combined Co. To Achieve Over $200M In Run-Rate Synergies Including $60M In Revenue Synergies

Comments

Virtus Real Asset Income ETF

Noticias

Últimas noticias sobre Virtus Real Asset Income ETF (ARCA:VRAI)

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL